Ajanta Pharma Ltd — Q4 FY26
Ajanta Pharma delivered a strong Q4 FY26 with revenue of ₹1,422 crore (+21% YoY) and PAT of ₹267 crore (+18% YoY).
bullish
high
✓ Verified against BSE filing
Indian management teams deliver on roughly 12% of specific earnings-call promises. A low score does not indicate dishonesty — it reflects how aspirational forward guidance typically is.
Q3 FY26
FY26 EBITDA margin guidance of 27%±1%
Management reiterated EBITDA margin guidance of 27%±1% for the full year, excluding forex mark-to-market impact.
Missed
Current-quarter commentary contains related risk or weakness, so the promise appears not to have been delivered yet.
heuristic_v1
Q3 FY26
FY26 gross margin guidance of 78%±1%
Gross margin expected to remain around 78%±1% for the full year.
Missed
Current-quarter commentary contains related risk or weakness, so the promise appears not to have been delivered yet.
heuristic_v1
Q3 FY26
FY26 capex guidance of ~₹300 crore
Capital expenditure for FY26 expected to be around ₹300 crore, with ₹235 crore spent in 9 months.
Missed
Current-quarter commentary contains related risk or weakness, so the promise appears not to have been delivered yet.
heuristic_v1
Q3 FY26
GLP-1 launch in India in March 2026
Company plans to launch GLP-1 products in India under own brand in March 2026, being in the first wave.
Missed
Current-quarter commentary contains related risk or weakness, so the promise appears not to have been delivered yet.
heuristic_v1